Searchable abstracts of presentations at key conferences in endocrinology

ea0097007 | Section | BES2023

Dose Reduction of Cyproterone Acetate in Trans Women and the Effect on Patient- reported Outcomes: Results from the ENIGI Study

Tim Flamant , Jeroen Vervalcke , Guy T'Sjoen

Context: Cyproterone acetate (CPA) is an androgen receptor blocker often used for testosterone suppression as a part of gender-affirming hormonal treatment (GAHT) in transgender women. In recent years, more concerns have been raised towards an increased risk of meningioma development, linked to CPA use in higher doses (25 mg or more per day).Objectives: To determine if lower doses of CPA are equally effective in maintain...